Isao Teshirogi, Shionogi president and CEO (Kiyoshi Ota/Bloomberg via Getty Images)
PhII Alzheimer's data looming, Shionogi spending up to $500M on a buyout involving one of the toughest bets in biotech
Shionogi moved a couple of months ago to get in tight with a low-profile biotech called Tetra Therapeutics in Grand Rapids, MI. And whatever …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
